New Panels Help Find Cause of Rapidly Progressive Dementia: Gregory (Gregg) Day, M.D.

Rapidly progressive dementia covers many conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' new evaluations help identify the cause of rapidly progressive dementia, to guide prognosis and treatment decisions.Show notesSpeaker 3: (00:32) Can you provide a little background about your role here at Mayo Clinic and experience with this disease state? Speaker 3: (01:21) Can you give us an understanding of rapidly progressive dementia? How is it different and what should physicians be looking for? Speaker 3: (03:13) You mentioned "syndromic" and that there are several diseases underneath that, one of them being Creutzfeldt-Jacob. Can you explain the others in a bit more detail? What makes them each unique under the heading of rapidly progressive dementias? Speaker 3: (05:29) Does that encompass it: prion diseases, then the neurodegenerative bucket, then autoimmune? Speaker 3: (06:03) Can you speak to the components of the new Creutzfeldt-Jacob disease-specific evaluation and the rapidly progressive dementia evaluation, and the assays that they're performed on? Speaker 3: (09:30) Anything you want to add to that summary of the assays' components? Speaker 3: (11:09) Can you explain the role — or lack thereof — of the 14-3-3 protein biomarker, according to our research? Speaker 3: (13:44) Which patients should get this testing, and who should not? Speaker 3: (17:22) What does it mean if the results come back positive and if the results come back negative? Speaker 3: (21:57) What are you most excited about with these tests?